Related content

The Ethics of Disclosing to Research Subjects the Availability of Off-Label Marketed Drugs

By Taylor Holly A.   Kuwana Ellen   Wilfond Benjamin S.  

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 51-51

Routledge Ltd

Access to resources Recommend Favorite

Researchers Have an Ethical Obligation to Disclose the Availability of Off-Label Marketed Drugs

By Silber Tomas J.  

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 52-52

Routledge Ltd

Access to resources Recommend Favorite

Marketing Off-Label Uses to Physicians: FDA's Draft (Mis)Guidance

By Gass Andy   Wilson Jennifer  

American Journal of Bioethics, Vol. 8, Iss. 3, 2008-03 ,pp. : 1-3

Routledge Ltd

Access to resources Recommend Favorite

Ethics of Continuing to Provide a Drug on an Open-Label Extension Study for an “Unapproved Indication”

By Taylor Holly A.   Kuwana Ellen   Wilfond Benjamin S.  

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 56-56

Routledge Ltd

Access to resources Recommend Favorite

The Context of Clinical Research and Its Ethical Relevance: The COMPAS Trial as a Case Study

By Camporesi Silvia   Mameli Matteo  

American Journal of Bioethics, Vol. 12, Iss. 1, 2012-01 ,pp. : 39-40

Routledge Ltd

Access to resources Recommend Favorite